Improvements of renal lesions and function by angiotensin and endothelin receptor antagonism in nitric oxide-deficient rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue SUPPL. 1, 2001, Pages

  Boffa, Jean Jacques ^a   Lu, Ying ^a   Dussaule, Jean Claude ^b   Chatziantoniou, Christos ^a  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Extracellular matrix; Hypertension; Nephroangiosclerosis; Regression of fibrosis

Indexed keywords

EID: 0242575687     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/14703203010020013701     Document Type: Article

References (35)

1. Weistuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int 1992;41:S33-S37.
2. Yoshioka K, Tohda M, Takemura T et al. Distribution of the type I collagen in human kidney diseases in comparison with type III collagen. J. Pathol 1990;162:141-8.
3. Anderson S, Meyer TW, Renke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-9.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
5. Border WA, Noble NA. Interactions of transforming growth factor-b and angiotensin II in renal fibrosis. Hypertension 1998;31:181-8.
6. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 1997;96:2407-13.
7. Garg UC, Hassid A. Nitric-oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
8. Xu Y, Arnal JF, Hinglais N et al. Renal hypertensive angiopathy. Comparison between chronic NO suppression and DOCA-salt intoxication. Am J Hypertens 1995;8:167-76.
9. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-81.
10. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78:225-8.
11. Chua BHL, Krebs KJ, Chua CC, Diglio CA. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 1992;262 (Endocrine Physiol. 31):E412-E416.
12. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708-12.
13. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy? Hypertension 1994;24:183-8.
14. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ETA-receptor antagonist. Circulation 1997;96:1593-7.
15. Bouriquet N, Dupont M, Herizi A, Mimran A, Casellas D. Preglomerular sudanophilia in L-NAME hypertensive rats: Involvement of endothelin. Hypertension 1996;27:382-91.
16. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice: Role of endothelin. J Clin Invest 1998;101:2780-9.
17. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 1999;100:1901-08.
18. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. Vascular endothelin-1 gene expression, synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999;99:2185-91.
19. Ju H, Dixon IMC. Effect of angiotensin II on myocardial collagen gene expression. Mol Cell Biochem 1996;163/164:231-7.
20. Takemoto M, Egashira K, Usui M et al. Important role of tissue angiotensin converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;99:278-87.
21. Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
22. Michel JB, Xu Y, Blot S, Philippe M, Chatellier G. Improved survival in rats administered L-NAME due to converting enzyme inhibition. J Cardiovasc Pharmacol 1996;281 42-8.
23. Benigni A, Zoja C, Corna D et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440-4.
24. Benigni A, Zoja C, Corna D et al. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996;27:416-23.
25. Verhagen AM, Rabelink TJ, Braam B et al. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J Am Soc Nephrol 1998;9:755-62.
26. Weber KT. Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation 2000;102:1342-5.
27. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991;69:107-15.
28. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996;28:269-75.
29. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
30. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000;36:200-25.
31. Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998;31:795-801.
32. Casellas D, Benhamed S, Artuso A, Jover B. Candesartan and progression of preglomerular lesions in L-NAME hypertensive rats. J Am Soc Nephrol 1999;10:S230-S233.
33. Fioretto P, Steffes MD, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75.
34. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 1998;54:353-9.
35. Cao Z, Cooper ME, Wu LL et al. Blockade of the reninangiotensin and endothelin systems on progressive renal injury. Hypertension 2000;36:561-8.